WO2007036802A3 - Sublingual dosage form comrising vitamin d analogue, in particular calcitriol - Google Patents

Sublingual dosage form comrising vitamin d analogue, in particular calcitriol Download PDF

Info

Publication number
WO2007036802A3
WO2007036802A3 PCT/IB2006/002853 IB2006002853W WO2007036802A3 WO 2007036802 A3 WO2007036802 A3 WO 2007036802A3 IB 2006002853 W IB2006002853 W IB 2006002853W WO 2007036802 A3 WO2007036802 A3 WO 2007036802A3
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
comrising
analogue
dosage form
sublingual dosage
Prior art date
Application number
PCT/IB2006/002853
Other languages
French (fr)
Other versions
WO2007036802A2 (en
Inventor
Moshe Flashner-Barak
Vered Rosenberger
Naomi Moldavski
Lerner E Itzhak
Original Assignee
Teva Pharma
Moshe Flashner-Barak
Vered Rosenberger
Naomi Moldavski
Lerner E Itzhak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Moshe Flashner-Barak, Vered Rosenberger, Naomi Moldavski, Lerner E Itzhak filed Critical Teva Pharma
Publication of WO2007036802A2 publication Critical patent/WO2007036802A2/en
Publication of WO2007036802A3 publication Critical patent/WO2007036802A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Disclosed are pharmaceutical dosage forms of vitamin D analogues, such as calcitriol, methods for their preparation and uses.
PCT/IB2006/002853 2005-07-07 2006-07-07 Sublingual dosage form comrising vitamin d analogue, in particular calcitriol WO2007036802A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0513984.5 2005-07-07
GBGB0513984.5A GB0513984D0 (en) 2005-07-07 2005-07-07 Dosage form

Publications (2)

Publication Number Publication Date
WO2007036802A2 WO2007036802A2 (en) 2007-04-05
WO2007036802A3 true WO2007036802A3 (en) 2007-08-30

Family

ID=34896899

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002853 WO2007036802A2 (en) 2005-07-07 2006-07-07 Sublingual dosage form comrising vitamin d analogue, in particular calcitriol

Country Status (2)

Country Link
GB (1) GB0513984D0 (en)
WO (1) WO2007036802A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2392338A4 (en) * 2009-01-30 2012-11-07 Teijin Pharma Ltd Prophylactic or therapeutic agent for diseases associated with abnormal bone metabolism
GB2469792A (en) * 2009-04-23 2010-11-03 Calvin John Ross Oil-based pharmaceutical formulation for sublingual delivery
PL2723344T3 (en) * 2011-08-19 2016-03-31 Maria Clementine Martin Klosterfrau Vertriebsges Mbh Monoterpene-containing agent for combination therapy
US9877929B2 (en) 2011-10-13 2018-01-30 Premier Dental Products Company Topical vitamin D and ubiquinol oral supplement compositions
US9724542B2 (en) 2012-10-12 2017-08-08 Premier Dental Products Company Remineralizing and desensitizing compositions, treatments and methods of manufacture
US9877930B2 (en) 2012-10-12 2018-01-30 Premier Dental Products Company Topical ubiquinol oral supplement compositions with amorphous calcium phosphate
WO2014059143A1 (en) * 2012-10-12 2014-04-17 Premier Dental Products Company Topical vitamin d and ubiquinol oral supplement compositions
WO2014113068A1 (en) * 2013-01-18 2014-07-24 Loma Linda University Compositions and methods for diagnosing and treating sepsis
CN103142486B (en) * 2013-03-21 2014-08-20 青岛正大海尔制药有限公司 Calcitriol powder and preparation method thereof
CN103142495B (en) * 2013-03-21 2014-08-20 青岛正大海尔制药有限公司 Calcitriol suspension granule and preparation method thereof
GB201414919D0 (en) * 2014-08-21 2014-10-08 Corbitt Terence Simon Formulations for transmucosal delivery
WO2022157385A1 (en) * 2021-01-25 2022-07-28 LDN Pharma Limited Naltrexone compositions
CN115350151B (en) * 2022-09-29 2023-09-12 湖北欣泽霏药业有限公司 High-stability alfacalcidol liquid oral preparation and preparation method thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014453A1 (en) * 1992-12-23 1994-07-07 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Hydroxy vitamin d3 compounds for treating skin atrophy
WO2000061112A2 (en) * 1999-04-13 2000-10-19 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Solubilized pharmaceutical composition for parenteral administration
WO2001046132A1 (en) * 1999-12-21 2001-06-28 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin d compounds for the prevention and treatment of inflammatory bowel disease
US6521608B1 (en) * 1998-03-27 2003-02-18 Oregon Health & Science University Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
WO2004019903A1 (en) * 2002-08-29 2004-03-11 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule containing drugs fortreating metabolic disorders
WO2004087190A1 (en) * 2003-04-02 2004-10-14 Genix Therapeutics Inc. Method for the treatment of prostate cancer
US20050009793A1 (en) * 2002-11-21 2005-01-13 Novacea, Inc. Treatment of liver disease with active vitamin D compounds
WO2005016872A1 (en) * 2003-06-11 2005-02-24 Novacea, Inc. Treatment of lung cancer with active vitamin d compounds in combination with other treatments
US20050054620A1 (en) * 2003-01-13 2005-03-10 Koeffler H. Phillip Paricalcitol as a chemotherapeutic agent
WO2006032053A2 (en) * 2004-09-14 2006-03-23 Teva Pharmaceutical Industries, Ltd. Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014453A1 (en) * 1992-12-23 1994-07-07 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Hydroxy vitamin d3 compounds for treating skin atrophy
US6521608B1 (en) * 1998-03-27 2003-02-18 Oregon Health & Science University Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
WO2000061112A2 (en) * 1999-04-13 2000-10-19 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Solubilized pharmaceutical composition for parenteral administration
WO2001046132A1 (en) * 1999-12-21 2001-06-28 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin d compounds for the prevention and treatment of inflammatory bowel disease
WO2004019903A1 (en) * 2002-08-29 2004-03-11 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule containing drugs fortreating metabolic disorders
US20050009793A1 (en) * 2002-11-21 2005-01-13 Novacea, Inc. Treatment of liver disease with active vitamin D compounds
US20050054620A1 (en) * 2003-01-13 2005-03-10 Koeffler H. Phillip Paricalcitol as a chemotherapeutic agent
WO2004087190A1 (en) * 2003-04-02 2004-10-14 Genix Therapeutics Inc. Method for the treatment of prostate cancer
WO2005016872A1 (en) * 2003-06-11 2005-02-24 Novacea, Inc. Treatment of lung cancer with active vitamin d compounds in combination with other treatments
WO2006032053A2 (en) * 2004-09-14 2006-03-23 Teva Pharmaceutical Industries, Ltd. Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LAROCHE M ET AL: "BENEFICIAL EFFECT ON BONE DENSITY IN MALE OSTEOPOROSIS OF POSTMENOPAUSAL OSTEOPOROSIS TREATMENT (FLUORIDE, ETIDRONATE, AND CALCITRIOL)", CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, PACINI, PISA, IT, vol. 16, no. 6, 1998, pages 760, XP008038157, ISSN: 0392-856X *
PLUM L A ET AL: "2MD, a new anabolic agent for osteoporosis treatment", OSTEOPOROSIS INTERNATIONAL 2006 UNITED KINGDOM, vol. 17, no. 5, 2006, pages 704 - 715, XP002430461, ISSN: 0937-941X 1433-2965 *
ROCHE HEXAGON: "ROCALTROL brand of calcitriol CAPSULES and ORAL SOLUTION", INTERNET ARTICLE, 20 November 1998 (1998-11-20), pages 1 - 10, XP002430463, Retrieved from the Internet <URL:HTTP://WWW.FDA.GOV/CDER/FOI/LABEL/1998/21068LBL.PDF> [retrieved on 20070420] *

Also Published As

Publication number Publication date
WO2007036802A2 (en) 2007-04-05
GB0513984D0 (en) 2005-08-17

Similar Documents

Publication Publication Date Title
WO2007036802A3 (en) Sublingual dosage form comrising vitamin d analogue, in particular calcitriol
IL192967A0 (en) Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2007044950A3 (en) Crystalline forms of docetaxel and processes for their preparation
WO2008005705A3 (en) Metal-containing formulations and methods of use
IL181618A0 (en) Pharmaceutical solid-in-oil compositions for external administraton, methods for preparation and uses thereof
IL181200A0 (en) Natural extract containing xanthohumol, and method for the production thereof and products produced therefrom
IL181301A0 (en) Cyclopamine analogues, pharmaceutical compositions comprising them and uses thereof
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
IL189008A (en) 1-naphthalenyl-3-azabicyclo[3.1.0]hexane derivatives, process for their preparation and pharmaceutical compositions comprising them
WO2008121767A3 (en) Stitched polypeptides
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2007114945A3 (en) Compositions and methods for enhancing the antioxidant status of animals
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
WO2006113568A8 (en) Controlled delivery dosage form of tramadol and gabapentin
PL382842A1 (en) Donepezili soles good for pharmaceutical compositions production
ZA200703376B (en) Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
WO2008027600A3 (en) Imatinib compositions
WO2007062370A3 (en) Calcilytic compounds
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
WO2007067784A3 (en) Liposomal compositions
WO2006091836A8 (en) Formulations of ladostigil tartrate
PL1707564T3 (en) Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0401522A2 (en) New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
HUP0401523A3 (en) Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
EP2035443A4 (en) Stabilized vitamin c derivatives having a peptide molecule, preparation method thereof, and composition containing the same

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06831544

Country of ref document: EP

Kind code of ref document: A2